)
Visual
test
Nkarta
Nkarta (NKTX) investor relations material
Nkarta Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary25 Mar, 2026
Executive summary
Advanced dose escalation for NKX019 to 4 billion cells per dose, totaling 12 billion cells per cycle, in ongoing clinical trials for autoimmune diseases.
Enrollment continued in Ntrust-1 and Ntrust-2 trials, with initial clinical data expected to be presented at a medical conference in 2026.
Workforce was right-sized and a clinical team with autoimmune expertise was onboarded to support strategic goals.
Financial highlights
Cash, cash equivalents, restricted cash, and investments totaled $295.1 million as of December 31, 2025.
Research and development expenses were $90.4 million for 2025 and $25.3 million for Q4 2025.
General and administrative expenses were $31.6 million for 2025 and $5.7 million for Q4 2025.
Net loss was $104.1 million ($1.41 per share) for 2025 and $27.4 million ($0.37 per share) for Q4 2025, including non-cash charges primarily from share-based compensation and depreciation.
Outlook and guidance
Cash balance is expected to fund operations into 2029.
Focus remains on disciplined clinical execution and continued enrollment in Ntrust-1 and Ntrust-2.
Rationale for the 12 billion cell dose target
Single-agent activity without cytokines
Assumptions behind the 2029 cash runway
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nkarta
- Biotech seeks up to $350M for NK cell therapy pipeline, with $100M ATM via Stifel.NKTX
Registration filing25 Mar 2026 - Focused on CD19 NK cell therapy for autoimmune disease, advancing toward pivotal trials and outpatient care.NKTXLeerink Global Healthcare Conference 202610 Mar 2026
- Allogeneic NK cell therapy advances with strong safety, pivotal data expected this year.NKTXTD Cowen 46th Annual Health Care Conference2 Mar 2026
- Allogeneic CAR NK therapy advances in autoimmune diseases, with key data expected in 2025.NKTXH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Leading allogeneic NK cell trials in autoimmune disease, prioritizing safety and drug-free remission.NKTXStifel 2024 Healthcare Conference13 Jan 2026
- Robust, safe, off-the-shelf NK cell therapy targets I&I with key data expected in 2025.NKTX7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026
- Allogeneic CAR-NK cells show promise for safe, flexible autoimmune therapy with broad potential.NKTXTD Cowen 45th Annual Healthcare Conference26 Dec 2025
- Allogeneic CAR-NK therapies show strong safety and scalability for autoimmune diseases, with key data ahead.NKTX24th Annual Needham Virtual Healthcare Conference23 Dec 2025
- Robust I&I data expected next year, with accelerated enrollment and strong financial runway.NKTXEvercore ISI 8th Annual HealthCONx Conference7 Dec 2025
Next Nkarta earnings date
Q1 202611 May, 2026
Nkarta
Next Nkarta earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage